USANA Health Sciences (NYSE:USNA) PT Lowered to $46.00 at DA Davidson

USANA Health Sciences (NYSE:USNA) had its price objective cut by DA Davidson from $48.00 to $46.00 in a research note published on Tuesday morning, Benzinga reports. They currently have a neutral rating on the stock. DA Davidson also issued estimates for USANA Health Sciences’ Q2 2024 earnings at $0.68 EPS.

Separately, StockNews.com upgraded shares of USANA Health Sciences from a buy rating to a strong-buy rating in a report on Friday, January 12th.

USANA Health Sciences Stock Performance

Shares of USNA opened at $44.74 on Tuesday. USANA Health Sciences has a fifty-two week low of $41.45 and a fifty-two week high of $69.60. The company has a market capitalization of $858.91 million, a PE ratio of 13.94, a price-to-earnings-growth ratio of 1.38 and a beta of 0.94. The stock has a fifty day moving average of $46.48 and a two-hundred day moving average of $48.07.

USANA Health Sciences (NYSE:USNA) last released its earnings results on Tuesday, February 6th. The company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.52 by $0.35. The firm had revenue of $221.08 million for the quarter, compared to the consensus estimate of $206.70 million. USANA Health Sciences had a return on equity of 12.80% and a net margin of 6.88%. As a group, equities research analysts forecast that USANA Health Sciences will post 2.75 earnings per share for the current fiscal year.

Insider Buying and Selling

In other USANA Health Sciences news, CFO G Doug Iiekking sold 5,198 shares of the business’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $44.76, for a total transaction of $232,662.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other USANA Health Sciences news, CFO G Doug Iiekking sold 5,198 shares of the business’s stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $44.76, for a total transaction of $232,662.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Daniel A. Macuga sold 3,791 shares of the stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $47.14, for a total transaction of $178,707.74. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 34,286 shares of company stock valued at $1,634,010. 0.33% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On USANA Health Sciences

A number of institutional investors have recently made changes to their positions in USNA. Quest Partners LLC acquired a new position in USANA Health Sciences during the 4th quarter worth $66,000. CWM LLC grew its holdings in shares of USANA Health Sciences by 49.6% during the fourth quarter. CWM LLC now owns 1,267 shares of the company’s stock valued at $68,000 after purchasing an additional 420 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in USANA Health Sciences by 60.6% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,376 shares of the company’s stock worth $198,000 after buying an additional 1,274 shares during the last quarter. Trexquant Investment LP acquired a new stake in shares of USANA Health Sciences in the 4th quarter worth about $266,000. Finally, Teacher Retirement System of Texas acquired a new stake in shares of USANA Health Sciences in the third quarter valued at approximately $297,000. 54.25% of the stock is owned by institutional investors and hedge funds.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.